Skip to main content
. 2016 May 14;8(11):18399–18408. doi: 10.18632/oncotarget.9369

Figure 3. Association between neoadjuvant chemotherapy regimens and relapse-free survival and overall survival.

Figure 3

The blue solid line represents patients with taxane-based regimens (A); the green solid line represents patients with anthracycline-based regimens (B). Adjusted for tumor size (T1-2 vs. T3-4) and clinical lymph node status (positive vs. negative) before neoadjuvant. HR: hazard ratio.